Research demonstrates potential method to better control lung cancer using radiotherapy

August 28, 2014 by Alison Barbuti

Manchester scientists are working out how to safely increase the radiotherapy dose given to lung cancer patients – potentially offering improved local control and survival.

Standard for locally advanced non-small cell lung cancer is a combination of and chemotherapy. Traditionally this is planned in a one-size-fits-all manner but the radiation dose may not always be enough to stop tumour growth.

The potential to increase the radiation dose to the cancerous tissue varies between patients and depends on the size and location of the tumour in relation to sensitive organs such as the spinal cord and lungs. Now researchers at The University of Manchester and The Christie NHS Foundation Trust – both part of the Manchester Cancer Research Centre – have looked at ways to personalise and increase the dose to the tumour while minimising the effect on healthy tissue.

Dr Corinne Faivre-Finn, researcher at The University of Manchester and Honorary Consultant at The Christie, who led the study, said: "Current standard options for the treatment of non-small cell lung cancer are associated with poor survival. We wanted to see if more advanced methods of planning and delivering radiotherapy treatment could potentially allow an increase in radiation dose."

The group used data from 20 to investigate whether a newer radiotherapy technique – intensity modulated radiotherapy (IMRT) – could potentially be used to increase the radiation dose to lung tumours, without harming healthy organs. Their treatment planning methods ensured a safe radiation dose was delivered to the surrounding organs at risk.

In an article recently published in the journal Clinical Oncology, they show that IMRT allowed an increase in radiation dose for non-small cell lung cancer.

"Our exploratory study suggests that using IMRT can allow to be increased: calculations indicate that this could yield a 10% improvement in tumour control. We are starting a new clinical trial, funded by Cancer Research UK, investigating the delivery of this personalised IMRT treatment in patients with non-small cell . We hope to demonstrate that the increase dose delivered to the tumour will lead to improved survival " added Dr Faivre-Finn.

Explore further: Experimental 'pulse radiotherapy' kills cancer cells while sparing healthy tissue

More information: "An Isotoxic Planning Comparison Study for Stage II-III Non-small Cell Lung Cancer: Is Intensity-modulated Radiotherapy the Answer?" Warren et al. Clin Oncol (R Coll Radiol). 2014 May 1. pii: S0936-6555(14)00094-6. DOI: 10.1016/j.clon.2014.03.011.

Related Stories

Experimental 'pulse radiotherapy' kills cancer cells while sparing healthy tissue

July 17, 2014
(Medical Xpress)—French researchers have developed a new radiation technique that appears to target tumour cells while leaving healthy cells unharmed, according to a new study in mice. 

Increased risk of developing lung cancer after radiotherapy for breast cancer

April 7, 2014
Vienna, Austria: Women who have radiotherapy for breast cancer have a small but significantly increased risk of subsequently developing a primary lung tumour, and now research has shown that this risk increases with the amount ...

New drug active against most aggressive type of lung cancer cells

July 10, 2014
(Medical Xpress)—Manchester scientists have shown that a new drug could prove useful in treating small cell lung cancer - the most aggressive form of lung cancer.

Higher radiation dose does not help lung cancer patients live longer

October 3, 2011
A higher dose of radiation (74 Gy) does not improve overall survival for non-small cell lung cancer that has spread to the lymph nodes, compared to the standard radiation dose (60 Gy), according to an interim analysis of ...

New agent may enhance effectiveness of radiotherapy

May 13, 2014
Scientists from The University of Manchester – part of the Manchester Cancer Research Centre - have demonstrated the potential of a drug to improve the effectiveness of radiotherapy in stopping tumour growth.

Dose-escalated hypofractionated IMRT, conventional IMRT for prostate cancer have like side effects

April 3, 2014
Dose-escalated intensity modulated radiation therapy (IMRT) with use of a moderate hypofractionation regimen (72 Gy in 2.4 Gy fractions) can safely treat patients with localized prostate cancer with limited grade 2 or 3 late ...

Recommended for you

Study uncovers potential 'silver bullet' for preventing and treating colon cancer

July 26, 2017
In preclinical experiments, researchers at VCU Massey Cancer Center have uncovered a new way in which colon cancer develops, as well as a potential "silver bullet" for preventing and treating it. The findings may extend to ...

Compound shows promise in treating melanoma

July 26, 2017
While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward ...

Understanding cell segregation mechanisms that help prevent cancer spread

July 26, 2017
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.